Patent · US Active

Organic compounds

US8710216B2 · kind B2 · utility

0Cited by

4References

3Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Pascale Hoehn · Eschentzwiller, FR
Bernd Koch · Berlin, DE
Michael Mutz · Glückstadt, DE

Key dates

Filing date	May 15, 2012
Grant date	Apr 29, 2014
Priority date	—
Expiry date	May 15, 2032

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a new crystalline form II of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of crystalline form II of of N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to the amorphous forms of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of amorphous N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.